Ignite Creation Date:
2024-05-06 @ 8:41 AM
Last Modification Date:
2024-10-26 @ 12:03 PM
Study NCT ID:
NCT02790450
Status:
COMPLETED
Last Update Posted:
2016-12-23
First Post:
2016-05-30
Brief Title:
Acute Effects of Benzbromaron on the Pulmonary Circulation
Sponsor:
Medical University of Graz
Organization:
Medical University of Graz
Study Overview
Official Title:
Acute Effects of Benzbromaron on the Pulmonary Circulation
Status:
COMPLETED
Status Verified Date:
2016-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Actual studies suggest that a calcium activated chlorid channel TMEM16A may play a relevant role in the pathogenesis of pulmonary arterial hypertension PAH The inhibition of this channel led to pulmonary vasorelaxation in preclinical studies Benzbromarone is a well known inhibitor of the TMEM16A channel and is used in patients with gout
In this pilot study the investigators plan to investigate if Benzbromarone has an acute effect on the pulmonary arteries in humans This will be investigated within the frame of a right heart catheterization performed in patients with known PAH due to clinical reasons The investigators hypothesize that the application of Benzbromarone leads to pulmonary vasodilation which can be recognized by the decrease in pulmonary vascular resistance In addition the change in pulmonary and systemic arterial pressure pulmonary arterial wedge pressure heart rate and arterial oxygen saturation will be assessed Due to clinical reasons patients will receive NO 15 ppm during right heart catheterization Hemodynamic changes upon NO and Benzbromarone may be compared
In this pilot study the investigators plan to investigate if Benzbromarone has an acute effect on the pulmonary arteries in humans This will be investigated within the frame of a right heart catheterization performed in patients with known PAH due to clinical reasons The investigators hypothesize that the application of Benzbromarone leads to pulmonary vasodilation which can be recognized by the decrease in pulmonary vascular resistance In addition the change in pulmonary and systemic arterial pressure pulmonary arterial wedge pressure heart rate and arterial oxygen saturation will be assessed Due to clinical reasons patients will receive NO 15 ppm during right heart catheterization Hemodynamic changes upon NO and Benzbromarone may be compared
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None